Skip to main content
Premium Trial:

Request an Annual Quote

A Mosaic of Uncertainty

Targeted therapies are only as good as the tests that determine whether they are warranted, says this article in the New York Times. In it, Linda Griffith, the head of MIT's Center for Gynepathology Research, says that she has seen this both as a researcher and as a patient. Her Her2 test on a breast biopsy came back as a mosaic and whether or not she should take Herceptin was unclear. In addition, a Mayo clinic study a few years ago found that labs often disagreed on the test results, and that led to the adoption of Her2 testing guidelines, though there can still be incongruities about results. Genentech's Krysta Pellegrino tells the Times that "we're still trying to refine the testing."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.